MA35698B1 - Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs. - Google Patents

Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.

Info

Publication number
MA35698B1
MA35698B1 MA35915A MA35915A MA35698B1 MA 35698 B1 MA35698 B1 MA 35698B1 MA 35915 A MA35915 A MA 35915A MA 35915 A MA35915 A MA 35915A MA 35698 B1 MA35698 B1 MA 35698B1
Authority
MA
Morocco
Prior art keywords
diaminopyridine
fatigability
disorders
muscular
treatment
Prior art date
Application number
MA35915A
Other languages
English (en)
Inventor
Benziane Hamid
E Douard Bruno
Flocard Frederic
Original Assignee
Univ Mohammed V Souissi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mohammed V Souissi filed Critical Univ Mohammed V Souissi
Priority to MA35915A priority Critical patent/MA35698B1/fr
Priority to PCT/MA2013/000041 priority patent/WO2014185761A1/fr
Publication of MA35698B1 publication Critical patent/MA35698B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L’objet de l’invention concerne une nouvelle composition du 3,4-diaminopyridine (3,4-dap) la rendant stable et homogène, préparée sous forme de gélule pour traiter et maîtriser l’évolution du syndrome paranéoplasique myasthénique de lambert-eaton, caractérisé par une fatigabilité musculaire associée à des troubles neurovégétatifs. Ce médicament est aussi utilisé dans la fatigabilité de la sclérose en plaques, dans le botulisme et les syndromes myasthéniques congénitaux et dans les troubles d’alzheimer. La nouveauté intéresse aussi le protocole de dosage du principe actif et des excipients. La nouvelle composition du 3,4-dap le mélange est délivré sous forme de gélule, comprimé ou suspension buvable, ou autres formes galéniques.
MA35915A 2013-05-16 2013-05-16 Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs. MA35698B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MA35915A MA35698B1 (fr) 2013-05-16 2013-05-16 Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.
PCT/MA2013/000041 WO2014185761A1 (fr) 2013-05-16 2013-12-05 Nouvelle composition du 3,4-diaminopyridine pour le traitement de la fatigabilite musculaire associee a des troubles neurovegetatifs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA35915A MA35698B1 (fr) 2013-05-16 2013-05-16 Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.

Publications (1)

Publication Number Publication Date
MA35698B1 true MA35698B1 (fr) 2014-12-01

Family

ID=49943449

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35915A MA35698B1 (fr) 2013-05-16 2013-05-16 Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.

Country Status (2)

Country Link
MA (1) MA35698B1 (fr)
WO (1) WO2014185761A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110548023A (zh) * 2019-09-19 2019-12-10 天津科技大学 胭脂虫红酸在制备抑制β-淀粉样蛋白聚集中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
WO2000047210A1 (fr) * 1999-02-09 2000-08-17 Uab Research Foundation Utilisation de 4-amino pyridine pour le traitement de neuropathies peripheriques

Also Published As

Publication number Publication date
WO2014185761A1 (fr) 2014-11-20

Similar Documents

Publication Publication Date Title
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MX2021004431A (es) Procesos novedosos.
EA202090573A1 (ru) Составы нирапариба
JP2015517488A5 (fr)
PH12021551541A1 (en) Compositions and methods for treating neurodegenerative disorders
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
EA202090276A1 (ru) Фармацевтическая композиция для лечения анемии
JP2016027060A5 (fr)
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
WO2017134685A3 (fr) Nouveaux composés hydrazino utilisés comme inhibiteurs de btk
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
EA201792237A1 (ru) Фармацевтические составы
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
JP2019529569A5 (fr)
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti
MA35698B1 (fr) Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
WO2017168454A3 (fr) Nouveaux composés utilisés comme inhibiteurs de btk
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
EA201792170A1 (ru) Производные индола
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.